Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
Mark J. Levis(Johns Hopkins University), Kristy Burns(Daiichi Sankyo (United States)), Jörge E. Cortes(Augusta University Health), Alexander E. Perl(University of Pennsylvania), Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), Elżbieta Patkowska(Institute for Transfusion Medicine), Hervé Dombret(University of London Institute in Paris), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Liu(Daiichi Sankyo (United States)), Abderrahmane Laadem(Daiichi Sankyo (India)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 5
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k